Graham Craig
About Graham Craig
Graham Craig is an Associate Director of Corporate Development at AbCellera, specializing in strategic forecasting and valuation within the pharmaceutical, crop science, and biotech sectors. With over a decade of experience in strategic consulting, he has held various roles at IMS Consulting Group and STEMCELL Technologies, focusing on pharmaceutical research and development, M&A due diligence, and R&D portfolio valuations.
Current Role at AbCellera
Graham Craig serves as the Associate Director of Corporate Development at AbCellera, a position he has held since 2020. In this role, he focuses on strategic forecasting and valuation within the biotech sector. His expertise contributes to the company's efforts in advancing therapeutic development through innovative technology.
Previous Experience in Consulting
Prior to his current role, Graham Craig accumulated extensive experience at IMS Consulting Group. He worked there in various capacities, including Analyst, Consultant, Senior Consultant, and Engagement Manager, from 2007 to 2014. His work involved pharmaceutical product forecasting and M&A due diligence, which provided him with a solid foundation in strategic consulting.
Experience at STEMCELL Technologies
Graham Craig held two significant roles at STEMCELL Technologies. He served as Senior Manager of Business Operations from 2015 to 2018 and later as Associate Director of Corporate Development from 2018 to 2020. His responsibilities included overseeing business operations and contributing to corporate development strategies in the biotech industry.
Educational Background
Graham Craig holds a Master of Science in Pharmaceutical Science from the University of British Columbia, where he studied from 2004 to 2006. He also earned a Bachelor of Science in Biochemistry from the University of York, completing his degree from 2000 to 2004. His academic background supports his expertise in the pharmaceutical and biotech sectors.
Specialization and Skills
Graham Craig specializes in strategic forecasting and valuation in the pharmaceutical, crop science, and biotech industries. He possesses a unique skill set that combines commercial awareness with scientific understanding, enabling him to navigate complex market dynamics and contribute to R&D portfolio valuations and organizational redesigns.